• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity

tetano

Editor, Senior Moderator
Cell Rep


. 2023 Jul 31;42(8):112888.
doi: 10.1016/j.celrep.2023.112888. Online ahead of print. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity

Alexander Muik[SUP] 1 [/SUP], Bonny Gaby Lui[SUP] 1 [/SUP], Jasmin Quandt[SUP] 1 [/SUP], Huitian Diao[SUP] 2 [/SUP], Yunguan Fu[SUP] 3 [/SUP], Maren Bacher[SUP] 1 [/SUP], Jessica Gordon[SUP] 1 [/SUP], Aras Toker[SUP] 1 [/SUP], Jessica Grosser[SUP] 1 [/SUP], Orkun Ozhelvaci[SUP] 1 [/SUP], Katharina Grikscheit[SUP] 4 [/SUP], Sebastian Hoehl[SUP] 4 [/SUP], Niko Kohmer[SUP] 4 [/SUP], Yaniv Lustig[SUP] 5 [/SUP], Gili Regev-Yochay[SUP] 6 [/SUP], Sandra Ciesek[SUP] 7 [/SUP], Karim Beguir[SUP] 3 [/SUP], Asaf Poran[SUP] 2 [/SUP], Isabel Vogler[SUP] 1 [/SUP], Özlem Türeci[SUP] 8 [/SUP], Ugur Sahin[SUP] 9 [/SUP]



Affiliations
Abstract

Evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has led to the emergence of sublineages with different patterns of neutralizing antibody evasion. We report that Omicron BA.4/BA.5 breakthrough infection of individuals immunized with SARS-CoV-2 wild-type-strain-based mRNA vaccines results in a boost of Omicron BA.4.6, BF.7, BQ.1.1, and BA.2.75 neutralization but does not efficiently boost BA.2.75.2, XBB, or XBB.1.5 neutralization. In silico analyses showed that the Omicron spike glycoprotein lost most neutralizing B cell epitopes, especially in sublineages BA.2.75.2, XBB, and XBB.1.5. In contrast, T cell epitopes are conserved across variants including XBB.1.5. T cell responses of mRNA-vaccinated, SARS-CoV-2-naive individuals against the wild-type strain, Omicron BA.1, and BA.4/BA.5 were comparable, suggesting that T cell immunity against recent sublineages including XBB.1.5 may remain largely unaffected. While some Omicron sublineages effectively evade B cell immunity, spike-protein-specific T cell immunity, due to the nature of polymorphic cell-mediated immune responses, may continue to contribute to prevention/limitation of severe COVID-19 manifestation.

Keywords: CP: Immunology; SARS-CoV-2; T cell immunity; epitope conservedness; immune escape; neutralizing antibodies.

 
Back
Top Bottom